Press Release

Sanofi accelerates global shipping of Beyfortus to prepare
healthcare providers months ahead of 2025-2026 RSV
season
Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure
broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which
typically starts in November and runs through March. Immunizations begin in early fall and
these advance shipments provide confidence for healthcare providers to support their efforts.
Demand has continued to increase since the launch of Beyfortus, the only option that can offer
RSV protection designed for all infants with proven high, sustained efficacy through a typical
RSV season and an unparalleled body of real-world evidence.

Sanofi, in collaboration with its partner AstraZeneca, has tripled production capacity and
doubled the number of manufacturing sites since the launch of Beyfortus in 2023. Current
supply for the upcoming season already matches the total doses distributed last year and
production continues. Last season in the US, enough doses were produced to cover every
infant — a benchmark that reflects both Sanofi’s and AstraZeneca’s global commitment to
ensuring timely access for all infants.

Thomas Triomphe
Executive Vice President, Vaccines
“Our third year of providing RSV protection marks a transformative era in infant health. Backed
by more than 40 real-world studies involving 250,000 immunized infants, Beyfortus has
consistently proven itself as an effective RSV immunization. To meet growing demand since
launch, we have meticulously primed our global distribution network to ensure Beyfortus will
continue to deliver significant public health impact and offer high, sustained efficacy for infants
regardless of underlying health conditions or the timing of when they are born.”

Beyfortus duration of protection extended through six months in the EU
This year’s EU shipments are marked by an important change to the Beyfortus EU label
extending the duration of protection through six months, so Beyfortus can continue to offer
season-long protection for all infants, including older babies immunized just before the RSV
season begins. More than six million babies have been immunized worldwide and millions more
will be immunized this season in more than 40 countries to help protect them from the
potentially devastating impact of RSV disease.

All infants are at risk from RSV
RSV is a highly contagious virus infecting two out of three infants in their first year of life and
nearly all children by their second birthday. RSV is the main cause of lower respiratory tract
disease and a leading cause of hospitalization in all infants worldwide, with most
hospitalizations occurring in healthy infants born at term.

With an extended half-life of 71 days, Beyfortus stands apart as the longest-acting monoclonal
antibody for the prevention of RSV lower respiratory tract disease in infants, and the only RSV
immunization designed to protect all infants born before or during the RSV season, at term or
preterm, healthy or with underlying conditions. Administration can be timed to coincide with
the RSV season and provided directly to newborns and infants as a single dose. Beyfortus
offers rapid protection without requiring activation of the immune system. Beyfortus is also
designed to protect children up to 24 months of age who remain vulnerable to severe RSV
disease through their second RSV season. Beyfortus was approved and granted special
designations to expedite development across major geographies including the US, the EU,
Japan and China.



1/2
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s
lives and delivering compelling growth. We apply our deep understanding of the immune
system to invent medicines and vaccines that treat and protect millions of people around the
world, with an innovative pipeline that could benefit millions more. Our team is guided by one
purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive
progress and deliver positive impact for our people and the communities we serve, by
addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com

Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | +1 617 710 3587 | tarik.elgoutni@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com



Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding
the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements
are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions.
Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors
are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include
among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing,
unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related
future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global
crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them,
as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed
or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024.
Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information
or statements.

All trademarks mentioned in this press release are the property of the Sanofi group.




2/2